{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["COVID-19", "dietary supplements", "drug repurposing", "heparin", "hydroxychloroquine", "lopinavir/ritonavir", "ozone", "pharmaceutical formulations", "phosphodiesterase inhibitors", "remdesivir"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "33668969", "DateRevised": {"Year": "2021", "Month": "04", "Day": "13"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "02", "Day": "25"}], "ELocationID": ["302", "10.3390/pharmaceutics13030302"], "Journal": {"ISSN": "1999-4923", "JournalIssue": {"Volume": "13", "Issue": "3", "PubDate": {"Year": "2021", "Month": "Feb", "Day": "25"}}, "Title": "Pharmaceutics", "ISOAbbreviation": "Pharmaceutics"}, "ArticleTitle": "Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.", "Abstract": {"AbstractText": ["COVID-19 may lead to severe respiratory distress syndrome and high risk of death in some patients. So far (January 2021), only the antiviral remdesivir has been approved, although no significant benefits in terms of mortality and clinical improvement were recently reported. In a setting where effective and safe treatments for COVID-19 are urgently needed, drug repurposing may take advantage of the fact that the safety profile of an agent is already well known and allows rapid investigation of the efficacy of potential treatments, at lower costs and with reduced risk of failure. Furthermore, novel pharmaceutical formulations of older agents (e.g., aerosolized administration of chloroquine/hydroxychloroquine, remdesivir, heparin, pirfenidone) have been tested in order to increase pulmonary delivery and/or antiviral effects of potentially active drugs, thus overcoming pharmacokinetic issues. In our review, we will highlight the importance of the drug repurposing strategy in the context of COVID-19, including regulatory and ethical aspects, with a specific focus on novel pharmaceutical formulations and routes of administration."]}, "AuthorList": [{"Identifier": ["0000-0003-3018-3779"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy."}], "LastName": "Gatti", "ForeName": "Milo", "Initials": "M"}, {"Identifier": ["0000-0002-0367-9595"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy."}], "LastName": "De Ponti", "ForeName": "Fabrizio", "Initials": "F"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceutics", "NlmUniqueID": "101534003", "ISSNLinking": "1999-4923"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270\u2013273. doi: 10.1038/s41586-020-2012-7.", "ArticleIdList": ["10.1038/s41586-020-2012-7", "PMC7095418", "32015507"]}, {"Citation": "WHO  WHO Director-General\u2019s Remarks at the Media Briefing on 2019-nCoV on 11 February 2020.  [(accessed on 22 November 2020)]; Available online:  https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020."}, {"Citation": "WHO  Virtual Press Conference on COVID-19\u201411 March 2020.  [(accessed on 22 November 2020)]; Available online:  https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic."}, {"Citation": "European Centre for Disease Prevention and Control  COVID-19 Situation Update Worldwide.  [(accessed on 11 January 2021)]; Available online:  https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases."}, {"Citation": "European Medicines Agency  First COVID-19 Treatment Recommended for EU Authorisation\u201425 June 2020.  [(accessed on 22 November 2020)]; Available online:  https://www.ema.europa.eu/en/documents/press-release/first-covid-19-treatment-recommended-eu-authorisation_en.pdf."}, {"Citation": "Food and Drug Administration  FDA\u2019s Approval of Veklury (Remdesivir) for the Treatment of COVID-19\u2014The Science of Safety and Effectiveness\u201422 October 2020.  [(accessed on 22 November 2020)]; Available online:  https://www.fda.gov/drugs/drug-safety-and-availability/fdas-approval-veklury-remdesivir-treatment-covid-19-science-safety-and-effectiveness."}, {"Citation": "Jorgensen S.C.J., Kebriaei R., Dresser L.D. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. 2020;40:659\u2013671. doi: 10.1002/phar.2429.", "ArticleIdList": ["10.1002/phar.2429", "PMC7283864", "32446287"]}, {"Citation": "CTS AIFA Rivaluter\u00e0 il Remdesivir Nella Terapia Anti Covid-19.  [(accessed on 22 November 2020)]; Available online:  https://www.aifa.gov.it/web/guest/-/cts-aifa-rivalutera-il-remdesivir-nella-terapia-anti-covid-19."}, {"Citation": "Pan H., Peto R., Karim Q.A., Alejandria M., Henao-Restrepo A.M., Garc\u00eda C.H., Kieny M.-P., Malekzadeh R., Murthy S., Preziosi M.-P., et al.  Repurposed antiviral drugs for COVID-19\u2014Interim WHO SOLIDARITY Trial Results.  [(accessed on 22 November 2020)];BMJ. 2020  doi: 10.1101/2020.10.15.20209817. Available online:  https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1.", "ArticleIdList": ["10.1101/2020.10.15.20209817v1", "10.1101/2020.10.15.20209817"]}, {"Citation": "Lamontagne F., Agoritsas T., Macdonald H., Leo Y.S., Diaz J., Agarwal A., Appiah J.A., Arabi Y., Blumberg L., Calfee C.S., et al. A living WHO guideline on drugs for covid-19. BMJ. 2020;370:m3379.", "ArticleIdList": ["32887691"]}, {"Citation": "Mahase E. Covid-19: Pfizer and BioNTech submit vaccine for US authorisation. BMJ. 2020;371:m4552. doi: 10.1136/bmj.m4552.", "ArticleIdList": ["10.1136/bmj.m4552", "33219049"]}, {"Citation": "Martin J.H., Bowden N.A. Drug repurposing in the era of COVID-19: A call for leadership and government investment. Med. J. Aust. 2020;212:450\u2013452.e1. doi: 10.5694/mja2.50603.", "ArticleIdList": ["10.5694/mja2.50603", "PMC7267456", "32372435"]}, {"Citation": "Cha Y., Erez T., Reynolds I.J., Kumar D., Ross J., Koytiger G., Kusko R., Zeskind B., Risso S., Kagan E., et al. Drug repurposing from the perspective of pharmaceutical companies. Br. J. Pharmacol. 2018;175:168\u2013180. doi: 10.1111/bph.13798.", "ArticleIdList": ["10.1111/bph.13798", "PMC5758385", "28369768"]}, {"Citation": "Pawar A.Y. Combating devastating COVID-19 by drug repurposing. Int. J. Antimicrob. Agents. 2020;56:105984. doi: 10.1016/j.ijantimicag.2020.105984.", "ArticleIdList": ["10.1016/j.ijantimicag.2020.105984", "PMC7162749", "32305589"]}, {"Citation": "Fan S., Xiao D., Wang Y., Liu L., Zhou X., Zhong W. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. Future Med. Chem. 2020;12:1565\u20131578. doi: 10.4155/fmc-2020-0158.", "ArticleIdList": ["10.4155/fmc-2020-0158", "PMC7341957", "32638628"]}, {"Citation": "Guy R.K., DiPaola R.S., Romanelli F., Dutch R.E. Rapid repurposing of drugs for COVID-19. Science. 2020;368:829\u2013830. doi: 10.1126/science.abb9332.", "ArticleIdList": ["10.1126/science.abb9332", "32385101"]}, {"Citation": "Abd El-Aziz T.M., Stockand J.D. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)\u2014An update on the status. Infect. Genet. Evol. 2020;83:104327. doi: 10.1016/j.meegid.2020.104327.", "ArticleIdList": ["10.1016/j.meegid.2020.104327", "PMC7166307", "32320825"]}, {"Citation": "Hossen M.S., Barek M.A., Jahan N., Safiqul Islam M. A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Compr. Clin. Med. 2020;2:1\u201313. doi: 10.1007/s42399-020-00485-9.", "ArticleIdList": ["10.1007/s42399-020-00485-9", "PMC7457893", "32904710"]}, {"Citation": "Yang Y., Islam M.S., Wang J., Li Y., Chen X. Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Int. J. Biol. Sci. 2020;16:1708\u20131717. doi: 10.7150/ijbs.45538.", "ArticleIdList": ["10.7150/ijbs.45538", "PMC7098036", "32226288"]}, {"Citation": "Italian Medicines Agency  Report on the Use of Drugs during COVID-19 Outbreak.  [(accessed on 22 November 2020)];2020 Jul 29; Available online:  https://www.aifa.gov.it/documents/20142/1202341/AIFA_Rapporto_uso_farmaci_durante_epidemia_COVID-19.pdf/39f3399f-3bb0-e02c-5149-286135cc4e44."}, {"Citation": "Alany R.G. COVID-19 pandemic: What can pharmaceutical formulation and drug delivery experts offer? Pharm. Dev. Technol. 2020;25:649. doi: 10.1080/10837450.2020.1764670.", "ArticleIdList": ["10.1080/10837450.2020.1764670", "32423342"]}, {"Citation": "Parvathaneni V., Gupta V. Utilizing drug repurposing against COVID-19\u2014Efficacy, limitations, and challenges. Life Sci. 2020;259:118275. doi: 10.1016/j.lfs.2020.118275.", "ArticleIdList": ["10.1016/j.lfs.2020.118275", "PMC7430345", "32818545"]}, {"Citation": "Ciliberto G., Cardone L. Boosting the arsenal against COVID-19 through computational drug repurposing. Drug Discov. Today. 2020;25:946\u2013948. doi: 10.1016/j.drudis.2020.04.005.", "ArticleIdList": ["10.1016/j.drudis.2020.04.005", "PMC7158822", "32304645"]}, {"Citation": "Singh T.U., Parida S., Lingaraju M.C., Kesavan M., Kumar D., Singh R.K. Drug repurposing approach to fight COVID-19. Pharmacol. Rep. 2020:1\u201330. doi: 10.1007/s43440-020-00155-6.", "ArticleIdList": ["10.1007/s43440-020-00155-6", "PMC7474498", "32889701"]}, {"Citation": "Pushpakom S., Iorio F., Eyers P.A., Escott K.J., Hopper S., Wells A., Doig A., Guilliams T., Latimer J., McNamee C., et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019;18:41\u201358. doi: 10.1038/nrd.2018.168.", "ArticleIdList": ["10.1038/nrd.2018.168", "30310233"]}, {"Citation": "Omolo C.A., Soni N., Fasiku V.O., Mackraj I., Govender T. Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. Eur. J. Pharmacol. 2020;883:173348. doi: 10.1016/j.ejphar.2020.173348.", "ArticleIdList": ["10.1016/j.ejphar.2020.173348", "PMC7334944", "32634438"]}, {"Citation": "Mohanty S., Harun Ai Rashid M., Mridul M., Mohanty C., Swayamsiddha S. Application of Artificial Intelligence in COVID-19 drug repurposing. Diabetes Metab. Syndr. 2020;14:1027\u20131031. doi: 10.1016/j.dsx.2020.06.068.", "ArticleIdList": ["10.1016/j.dsx.2020.06.068", "PMC7332938", "32634717"]}, {"Citation": "Mangione W., Falls Z., Melendy T., Chopra G., Samudrala R. Shotgun drug repurposing biotechnology to tackle epidemics and pandemics. Chem. Rxiv. 2020 doi: 10.1016/j.drudis.2020.05.002.", "ArticleIdList": ["10.1016/j.drudis.2020.05.002", "PMC7217781", "32405249"]}, {"Citation": "Ke Y.Y., Peng T.T., Yeh T.K., Huang W.Z., Chang S.E., Wu S.H., Hung H.C., Hsu T.A., Lee S.J., Song J.S., et al. Artificial intelligence approach fighting COVID-19 with repurposing drugs. Biomed. J. 2020;43:355\u2013362. doi: 10.1016/j.bj.2020.05.001.", "ArticleIdList": ["10.1016/j.bj.2020.05.001", "PMC7227517", "32426387"]}, {"Citation": "Richardson P., Griffin I., Tucker C., Smith D., Oechsle O., Phelan A., Rawling M., Savory E., Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30\u2013e31. doi: 10.1016/S0140-6736(20)30304-4.", "ArticleIdList": ["10.1016/S0140-6736(20)30304-4", "PMC7137985", "32032529"]}, {"Citation": "Sultana J., Crisafulli S., Gabbay F., Lynn E., Shakir S., Trifir\u00f2 G. Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front. Pharmacol. 2020;11:588654. doi: 10.3389/fphar.2020.588654.", "ArticleIdList": ["10.3389/fphar.2020.588654", "PMC7677570", "33240091"]}, {"Citation": "Bayoumy A.B., de Boer N.K.H., Ansari A.R., Crouwel F., Mulder C.J.J. Unrealized potential of drug repositioning in europe during COVID-19 and beyond: A physcian\u2019s perspective. J. Pharm. Policy Pract. 2020;13:45. doi: 10.1186/s40545-020-00249-9.", "ArticleIdList": ["10.1186/s40545-020-00249-9", "PMC7366879", "32695427"]}, {"Citation": "Murteira S., Millier A., Ghezaiel Z., Lamure M. Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: Regulatory implications. J. Mark. Access Health Policy. 2014;2:22813. doi: 10.3402/jmahp.v2.22813.", "ArticleIdList": ["10.3402/jmahp.v2.22813", "PMC4865781", "27226839"]}, {"Citation": "European Medicines Agency  COVID-19: How EMA Fast-Tracks Development Support and Approval of Medicines and Vaccines.  [(accessed on 26 November 2020)];2020 May 4; Available online:  https://www.ema.europa.eu/en/documents/press-release/covid-19-how-ema-fast-tracks-development-support-approval-medicines-vaccines_en.pdf."}, {"Citation": "European Medicines Agency  EMA Initiatives for Acceleration of Development Support and Evaluation Procedures for COVID-19 Treatments and Vaccines.  [(accessed on 26 November 2020)];2020 May 4; Available online:  https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf."}, {"Citation": "Saint-Raymond A., Sato J., Kishioka Y., Teixeira T., Hasslboeck C., Kweder S.L. Remdesivir emergency approvals: A comparison of the U.S., Japanese, and EU systems. Expert Rev. Clin. Pharmacol. 2020;13:1095\u20131101. doi: 10.1080/17512433.2020.1821650.", "ArticleIdList": ["10.1080/17512433.2020.1821650", "32909843"]}, {"Citation": "Medicines and Healthcare Products Regulatory Agency  MHRA Issues a Scientific Opinion for the First Medicine to Treat COVID-19 in the UK (26 May 2020)  [(accessed on 27 November 2020)]; Available online:  https://www.gov.uk/government/news/mhra-supports-the-use-of-remdesivir-as-the-first-medicine-to-treat-covid-19-in-the-uk."}, {"Citation": "Mucke H.A.M. COVID-19 and the Drug Repurposing Tsunami. Assay Drug Dev. Technol. 2020;18:211\u2013214. doi: 10.1089/adt.2020.996.", "ArticleIdList": ["10.1089/adt.2020.996", "32551883"]}, {"Citation": "Ino H., Nakazawa E., Akabayashi A. Drug Repurposing for COVID-19: Ethical Considerations and Roadmaps. Camb. Q. Healthc. Ethics. 2020;30:51\u201358. doi: 10.1017/S0963180120000481.", "ArticleIdList": ["10.1017/S0963180120000481", "PMC7373824", "32498751"]}, {"Citation": "Singh J.A., Upshur R.E.G. The granting of emergency use designation to COVID-19 candidate vaccines: Implications for COVID-19 vaccine trials. Lancet Infect. Dis. 2020 doi: 10.1016/S1473-3099(20)30923-3.", "ArticleIdList": ["10.1016/S1473-3099(20)30923-3", "PMC7832518", "33306980"]}, {"Citation": "Scuccimarri R., Sutton E., Fitzcharles M.A. Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. J. Rheumatol. 2020;47:783\u2013786. doi: 10.3899/jrheum.200369.", "ArticleIdList": ["10.3899/jrheum.200369", "32241801"]}, {"Citation": "Chen C., Pan K., Wu B., Li X., Chen Z., Xu Q., Li X., Lv Q. Safety of hydroxychloroquine in COVID-19 and other diseases: A systematic review and meta-analysis of 53 randomized trials. Eur. J. Clin. Pharmacol. 2021;77:13\u201324. doi: 10.1007/s00228-020-02962-5.", "ArticleIdList": ["10.1007/s00228-020-02962-5", "PMC7417776", "32780229"]}, {"Citation": "Singh J.A., Ravinetto R. COVID-19 therapeutics: How to sow confusion and break public trust during international public health emergencies. J. Pharm. Policy Pract. 2020;13:47. doi: 10.1186/s40545-020-00244-0.", "ArticleIdList": ["10.1186/s40545-020-00244-0", "PMC7379753", "32719731"]}, {"Citation": "Orienti I., Gentilomi G.A., Farruggia G. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment in COVID-19. Int. J. Mol. Sci. 2020;21:3812. doi: 10.3390/ijms21113812.", "ArticleIdList": ["10.3390/ijms21113812", "PMC7312074", "32471278"]}, {"Citation": "Kwok P.C., Chan H.K. Pulmonary drug delivery. Ther. Deliv. 2013;4:877\u2013878. doi: 10.4155/tde.13.89.", "ArticleIdList": ["10.4155/tde.13.89", "23919463"]}, {"Citation": "Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003;56:588\u2013599. doi: 10.1046/j.1365-2125.2003.01892.x.", "ArticleIdList": ["10.1046/j.1365-2125.2003.01892.x", "PMC1884307", "14616418"]}, {"Citation": "Lipworth B.J. Pharmacokinetics of inhaled drugs. Br. J. Clin. Pharmacol. 1996;42:697\u2013705. doi: 10.1046/j.1365-2125.1996.00493.x.", "ArticleIdList": ["10.1046/j.1365-2125.1996.00493.x", "PMC2042712", "8971424"]}, {"Citation": "Pindiprolu S.K., Kumar C.S., Golla V.S., Likitha P., Chandra S., Ramachandra R.K. Pulmonary delivery of nanostructured lipid carriers for effective repurposing of salinomycin as an antiviral agent. Med. Hypotheses. 2020;143:109858. doi: 10.1016/j.mehy.2020.109858.", "ArticleIdList": ["10.1016/j.mehy.2020.109858", "PMC7260485", "32516655"]}, {"Citation": "Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003;56:600\u2013612. doi: 10.1046/j.1365-2125.2003.01893.x.", "ArticleIdList": ["10.1046/j.1365-2125.2003.01893.x", "PMC1884297", "14616419"]}, {"Citation": "Tolman J.A., Williams R.O., 3rd Advances in the pulmonary delivery of poorly water-soluble drugs: Influence of solubilization on pharmacokinetic properties. Drug Dev. Ind. Pharm. 2010;36:1\u201330. doi: 10.3109/03639040903092319.", "ArticleIdList": ["10.3109/03639040903092319", "19640248"]}, {"Citation": "Kukut Hatipoglu M., Hickey A.J., Garcia-Contreras L. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. Int. J. Pharm. 2018;549:306\u2013316. doi: 10.1016/j.ijpharm.2018.07.050.", "ArticleIdList": ["10.1016/j.ijpharm.2018.07.050", "30077761"]}, {"Citation": "Groneberg D.A., Witt C., Wagner U., Chung K.F., Fischer A. Fundamentals of pulmonary drug delivery. Respir. Med. 2003;97:382\u2013387. doi: 10.1053/rmed.2002.1457.", "ArticleIdList": ["10.1053/rmed.2002.1457", "12693798"]}, {"Citation": "Yang M.Y., Chan J.G., Chan H.K. Pulmonary drug delivery by powder aerosols. J. Control Release. 2014;193:228\u2013240. doi: 10.1016/j.jconrel.2014.04.055.", "ArticleIdList": ["10.1016/j.jconrel.2014.04.055", "24818765"]}, {"Citation": "van Haren F.M.P., Page C., Laffey J.G., Artigas A., Camprubi-Rimblas M., Nunes Q., Smith R., Shute J., Carroll M., Tree J., et al. Nebulised heparin as a treatment for COVID-19: Scientific rationale and a call for randomised evidence. Crit. Care. 2020;24:454. doi: 10.1186/s13054-020-03148-2.", "ArticleIdList": ["10.1186/s13054-020-03148-2", "PMC7374660", "32698853"]}, {"Citation": "Paolisso P., Bergamaschi L., D\u2019Angelo E.C., Donati F., Giannella M., Tedeschi S., Pascale R., Bartoletti M., Tesini G., Biffi M., et al. Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. Front. Pharmacol. 2020;11:1124. doi: 10.3389/fphar.2020.01124.", "ArticleIdList": ["10.3389/fphar.2020.01124", "PMC7424043", "32848743"]}, {"Citation": "Kipshidze N., Iversen P., Porter T.R., Kipshidze N., Siddiqui F., Dangas G., Fareed J. Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. Clin. Appl. Thromb. Hemost. 2020;26:1076029620954911. doi: 10.1177/1076029620954911.", "ArticleIdList": ["10.1177/1076029620954911", "PMC7498969", "32936689"]}, {"Citation": "Higgins T.S., Wu A.W., Illing E.A., Sokoloski K.J., Weaver B.A., Anthony B.P., Hughes N., Ting J.Y. Intranasal Antiviral Drug Delivery and Coronavirus Disease 2019 (COVID-19): A State of the Art Review. Otolaryngol. Head Neck Surg. 2020;163:682\u2013694. doi: 10.1177/0194599820933170.", "ArticleIdList": ["10.1177/0194599820933170", "32660339"]}, {"Citation": "Pe\u00f1a-Silva R., Duffull S.B., Steer A.C., Jaramillo-Rincon S.X., Gwee A., Zhu X. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. Br. J. Clin. Pharmacol. 2020 doi: 10.1111/bcp.14476. online ahead of print.", "ArticleIdList": ["10.1111/bcp.14476", "PMC7404744", "32779815"]}, {"Citation": "Jermain B., Hanafin P.O., Cao Y., Lifschitz A., Lanusse C., Rao G.G. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. J. Pharm. Sci. 2020;109:3574\u20133578. doi: 10.1016/j.xphs.2020.08.024.", "ArticleIdList": ["10.1016/j.xphs.2020.08.024", "PMC7473010", "32891630"]}, {"Citation": "Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med. 2020;382:1787\u20131799. doi: 10.1056/NEJMoa2001282.", "ArticleIdList": ["10.1056/NEJMoa2001282", "PMC7121492", "32187464"]}, {"Citation": "McHugh K.J. Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID-19. Bioeng. Transl. Med. 2020;5:e10163. doi: 10.1002/btm2.10163.", "ArticleIdList": ["10.1002/btm2.10163", "PMC7235503", "32440566"]}, {"Citation": "Rameshrad M., Ghafoori M., Mohammadpour A.H., Nayeri M.J.D., Hosseinzadeh H. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19) Naunyn Schmiedebergs Arch. Pharmacol. 2020;393:1137\u20131152. doi: 10.1007/s00210-020-01901-6.", "ArticleIdList": ["10.1007/s00210-020-01901-6", "PMC7235439", "32430617"]}, {"Citation": "Kang J.E., Rhie S.J. Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. J. Clin. Pharm. Ther. 2020 doi: 10.1111/jcpt.13199. online ahead of print.", "ArticleIdList": ["10.1111/jcpt.13199", "PMC7307068", "32524645"]}, {"Citation": "Siddiqi H.K., Mehra M.R. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transplant. 2020;39:405\u2013407. doi: 10.1016/j.healun.2020.03.012.", "ArticleIdList": ["10.1016/j.healun.2020.03.012", "PMC7118652", "32362390"]}, {"Citation": "Tang W., Cao Z., Han M., Wang Z., Chen J., Sun W., Wu Y., Xiao W., Liu S., Chen E., et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label, randomised controlled trial. BMJ. 2020;369:m1849. doi: 10.1136/bmj.m1849.", "ArticleIdList": ["10.1136/bmj.m1849", "PMC7221473", "32409561"]}, {"Citation": "Mah\u00e9vas M., Tran V.T., Roumier M., Chabrol A., Paule R., Guillaud C., Fois E., Lepeule R., Szwebel T.A., Lescure F.X., et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: Observational comparative study using routine care data. BMJ. 2020;369:m1844. doi: 10.1136/bmj.m1844.", "ArticleIdList": ["10.1136/bmj.m1844", "PMC7221472", "32409486"]}, {"Citation": "Boulware D.R., Pullen M.F., Bangdiwala A.S., Pastick K.A., Lofgren S.M., Okafor E.C., Skipper C.P., Nascene A.A., Nicol M.R., Abassi M., et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N. Engl. J. Med. 2020;383:517\u2013525. doi: 10.1056/NEJMoa2016638.", "ArticleIdList": ["10.1056/NEJMoa2016638", "PMC7289276", "32492293"]}, {"Citation": "RECOVERY Collaborative Group. Horby P., Mafham M., Linsell L., Bell J.L., Staplin N., Emberson J.R., Wiselka M., Ustianowski A., Elmahi E., et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N. Engl. J. Med. 2020;383:2030\u20132040.", "ArticleIdList": ["PMC7556338", "33031652"]}, {"Citation": "D\u2019Acquarica I., Agranat I. Chiral switches of chloroquine and hydroxychloroquine: Potential drugs to treat COVID-19. Drug Discov. Today. 2020;25:1121\u20131123. doi: 10.1016/j.drudis.2020.04.021.", "ArticleIdList": ["10.1016/j.drudis.2020.04.021", "PMC7194068", "32371138"]}, {"Citation": "Lentini G., Cavalluzzi M.M., Habtemariam S. COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help. Molecules. 2020;25:1834. doi: 10.3390/molecules25081834.", "ArticleIdList": ["10.3390/molecules25081834", "PMC7221598", "32316270"]}, {"Citation": "Fan J., Zhang X., Liu J., Yang Y., Zheng N., Liu Q., Bergman K., Reynolds K., Huang S.M., Zhu H., et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: A critical step in treating COVID-19 patients. Clin. Infect. Dis. 2020;71:3232\u20133236. doi: 10.1093/cid/ciaa623.", "ArticleIdList": ["10.1093/cid/ciaa623", "PMC7314136", "32435791"]}, {"Citation": "Albariqi A.H., Chang R.Y.K., Tai W., Ke W.R., Chow M.Y.T., Tang P., Kwok P.C.L., Chan H.K. Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. J. Aerosol. Med. Pulm. Drug Deliv. 2020 doi: 10.1089/jamp.2020.1648. online ahead of print.", "ArticleIdList": ["10.1089/jamp.2020.1648", "33179983"]}, {"Citation": "Kavanagh O., Marie Healy A., Dayton F., Robinson S., O\u2019Reilly N.J., Mahoney B., Arthur A., Walker G., Farragher J.P. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. Med. Hypotheses. 2020;143:110110. doi: 10.1016/j.mehy.2020.110110.", "ArticleIdList": ["10.1016/j.mehy.2020.110110", "PMC7361049", "33017904"]}, {"Citation": "Fassihi S.C., Nabar N.R., Fassihi R. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19. Br. J. Pharmacol. 2020;177:4997\u20134998. doi: 10.1111/bph.15167.", "ArticleIdList": ["10.1111/bph.15167", "PMC7323163", "32562278"]}, {"Citation": "Tai T.T., Wu T.J., Wu H.D., Tsai Y.C., Wang H.T., Wang A.M., Shih S.F., Chen Y.C. A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Pre-clinical Pharmacokinetic Study. Clin. Transl. Sci. 2020 doi: 10.1111/cts.12923. online ahead of print.", "ArticleIdList": ["10.1111/cts.12923", "PMC7877818", "33135382"]}, {"Citation": "Musazzi U.M., Zanon D., Gennari C.M.G., Fortini M., Maximova N., Cilurzo F., Minghetti P. Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation. Data Brief. 2020;32:106116. doi: 10.1016/j.dib.2020.106116.", "ArticleIdList": ["10.1016/j.dib.2020.106116", "PMC7395607", "32802924"]}, {"Citation": "Derwand R., Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today\u2019s battle against COVID-19? Med. Hypotheses. 2020;142:109815. doi: 10.1016/j.mehy.2020.109815.", "ArticleIdList": ["10.1016/j.mehy.2020.109815", "PMC7202847", "32408070"]}, {"Citation": "Bailly C., Vergoten G. Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome? Pharmacol. Ther. 2020;214:107618. doi: 10.1016/j.pharmthera.2020.107618.", "ArticleIdList": ["10.1016/j.pharmthera.2020.107618", "PMC7311916", "32592716"]}, {"Citation": "Sun D. Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. AAPS J. 2020;22:77. doi: 10.1208/s12248-020-00459-8.", "ArticleIdList": ["10.1208/s12248-020-00459-8", "PMC7250281", "32458279"]}, {"Citation": "Contini C., Enrica Gallenga C., Neri G., Maritati M., Conti P. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application. Med. Hypotheses. 2020;144:109876. doi: 10.1016/j.mehy.2020.109876.", "ArticleIdList": ["10.1016/j.mehy.2020.109876", "PMC7246020", "32562915"]}, {"Citation": "Desideri I., Martinelli C., Ciuti S., Uccello Barretta G., Balzano F. Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy. Eur. J. Hosp. Pharm. 2020 doi: 10.1136/ejhpharm-2020-002389. online ahead of print.", "ArticleIdList": ["10.1136/ejhpharm-2020-002389", "PMC7677895", "33214132"]}, {"Citation": "Zanon D., Musazzi U.M., Manca A., De Nicol\u00f2 A., D\u2019Avolio A., Cilurzo F., Maximova N., Tomasello C., Clementi E., Minghetti P. Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients. Data Brief. 2020;33:106445. doi: 10.1016/j.dib.2020.106445.", "ArticleIdList": ["10.1016/j.dib.2020.106445", "PMC7582040", "33110933"]}, {"Citation": "Kumar S., Zhi K., Mukherji A., Gerth K. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. Viruses. 2020;12:486. doi: 10.3390/v12050486.", "ArticleIdList": ["10.3390/v12050486", "PMC7290948", "32357553"]}, {"Citation": "Vader P., Breakefield X.O., Wood M.J. Extracellular vesicles: Emerging targets for cancer therapy. Trends Mol. Med. 2014;20:385\u2013393. doi: 10.1016/j.molmed.2014.03.002.", "ArticleIdList": ["10.1016/j.molmed.2014.03.002", "PMC4082760", "24703619"]}, {"Citation": "Whyte C.S., Morrow G.B., Mitchell J.L., Chowdary P., Mutch N.J. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J. Thromb. Haemost. 2020;18:1548\u20131555. doi: 10.1111/jth.14872.", "ArticleIdList": ["10.1111/jth.14872", "PMC7264738", "32329246"]}, {"Citation": "Ayerbe L., Risco C., Ayis S. The association between treatment with heparin and survival in patients with Covid-19. J. Thromb. Thrombolysis. 2020;50:298\u2013301. doi: 10.1007/s11239-020-02162-z.", "ArticleIdList": ["10.1007/s11239-020-02162-z", "PMC7261349", "32476080"]}, {"Citation": "Wang J., Hajizadeh N., Moore E.E., McIntyre R.C., Moore P.K., Veress L.A., Yaffe M.B., Moore H.B., Barrett C.D. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. J. Thromb Haemost. 2020;18:1752\u20131755. doi: 10.1111/jth.14828.", "ArticleIdList": ["10.1111/jth.14828", "PMC7262152", "32267998"]}, {"Citation": "Colaneri M., Quarti A., Pozzi M., Gasparini S., Carloni I., de Benedictis F.M. Management of plastic bronchitis with nebulized tissue plasminogen activator: Another brick in the wall. Ital. J. Pediatr. 2014;40:18. doi: 10.1186/1824-7288-40-18.", "ArticleIdList": ["10.1186/1824-7288-40-18", "PMC3974171", "24524376"]}, {"Citation": "Leisch M., Egle A., Greil R. Plitidepsin: A potential new treatment for relapsed/refractory multiple myeloma. Future Oncol. 2019;15:109\u2013120. doi: 10.2217/fon-2018-0492.", "ArticleIdList": ["10.2217/fon-2018-0492", "30111169"]}, {"Citation": "Martinez M.A. Plitidepsin: A repurposed drug for the treatment of COVID-19. Antimicrob. Agents Chemother. 2021 doi: 10.1128/AAC.00200-21.", "ArticleIdList": ["10.1128/AAC.00200-21", "PMC8097422", "33558296"]}, {"Citation": "Solaimanzadeh I. Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19) Cureus. 2020;12:e7343. doi: 10.7759/cureus.7343.", "ArticleIdList": ["10.7759/cureus.7343", "PMC7096066", "32226695"]}, {"Citation": "Dalamaga M., Karampela I., Mantzoros C.S. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism. 2020;109:154282. doi: 10.1016/j.metabol.2020.154282.", "ArticleIdList": ["10.1016/j.metabol.2020.154282", "PMC7263254", "32497535"]}, {"Citation": "Bridgewood C., Damiani G., Sharif K., Watad A., Bragazzi N.L., Quartuccio L., Savic S., McGonagle D. Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond. ISR Med. Assoc. J. 2020;22:335\u2013339.", "ArticleIdList": ["32558435"]}, {"Citation": "Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506. doi: 10.1016/S0140-6736(20)30183-5.", "ArticleIdList": ["10.1016/S0140-6736(20)30183-5", "PMC7159299", "31986264"]}, {"Citation": "Mugheddu C., Pizzatti L., Sanna S., Atzori L., Rongioletti F. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: Safety and compatibility of apremilast with critical intensive care management. J. Eur. Acad Dermatol. Venereol. 2020;34:e376\u2013e378. doi: 10.1111/jdv.16625.", "ArticleIdList": ["10.1111/jdv.16625", "PMC7272987", "32385859"]}, {"Citation": "Maldonado V., Loza-Mej\u00eda M.A., Ch\u00e1vez-Alderete J. Repositioning of pentoxifylline as an immunomodulator and regulator of the renin-angiotensin system in the treatment of COVID-19. Med. Hypotheses. 2020;144:109988. doi: 10.1016/j.mehy.2020.109988.", "ArticleIdList": ["10.1016/j.mehy.2020.109988", "PMC7282759", "32540603"]}, {"Citation": "Thai A., Xiao J., Ammit A.J., Rohanizadeh R. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims. Int. J. Pharm. 2010;389:41\u201352. doi: 10.1016/j.ijpharm.2010.01.014.", "ArticleIdList": ["10.1016/j.ijpharm.2010.01.014", "20080165"]}, {"Citation": "Vitiello A., Pelliccia C., Ferrara F. COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy. SN Compr. Clin. Med. 2020;2:1709\u20131712. doi: 10.1007/s42399-020-00487-7.", "ArticleIdList": ["10.1007/s42399-020-00487-7", "PMC7452615", "32875276"]}, {"Citation": "Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. Med. Hypotheses. 2020;144:110005. doi: 10.1016/j.mehy.2020.110005.", "ArticleIdList": ["10.1016/j.mehy.2020.110005", "PMC7297676", "32575019"]}, {"Citation": "Artigas L., Coma M., Matos-Filipe P., Aguirre-Plans J., Farr\u00e9s J., Valls R., Fernandez-Fuentes N., de la Haba-Rodriguez J., Olvera A., Barbera J., et al. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. PLoS ONE. 2020;15:e0240149. doi: 10.1371/journal.pone.0240149.", "ArticleIdList": ["10.1371/journal.pone.0240149", "PMC7531795", "33006999"]}, {"Citation": "Khoo J.K., Montgomery A.B., Otto K.L., Surber M., Faggian J., Lickliter J.D., Glaspole I. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. J. Aerosol Med. Pulm. Drug Deliv. 2020;33:15\u201320. doi: 10.1089/jamp.2018.1507.", "ArticleIdList": ["10.1089/jamp.2018.1507", "PMC7041323", "30698487"]}, {"Citation": "Kaminskas L.M., Landersdorfer C.B., Bischof R.J., Leong N., Ibrahim J., Davies A.N., Pham S., Beck S., Montgomery A.B., Surber M.W. Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis. Pharm. Res. 2019;37:3. doi: 10.1007/s11095-019-2732-2.", "ArticleIdList": ["10.1007/s11095-019-2732-2", "31823096"]}, {"Citation": "Adams K.K., Baker W.L., Sobieraj D.M. Myth Busters: Dietary Supplements and COVID-19. Ann. Pharmacother. 2020;54:820\u2013826. doi: 10.1177/1060028020928052.", "ArticleIdList": ["10.1177/1060028020928052", "PMC8685478", "32396382"]}, {"Citation": "Huang F., Li Y., Leung E.L., Liu X., Liu K., Wang Q., Lan Y., Li X., Yu H., Cui L., et al. A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19) Pharmacol. Res. 2020;158:104929. doi: 10.1016/j.phrs.2020.104929.", "ArticleIdList": ["10.1016/j.phrs.2020.104929", "PMC7237953", "32442720"]}, {"Citation": "Infusino F., Marazzato M., Mancone M., Fedele F., Mastroianni C.M., Severino P., Ceccarelli G., Santinelli L., Cavarretta E., Marullo A.G.M., et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients. 2020;12:1718. doi: 10.3390/nu12061718.", "ArticleIdList": ["10.3390/nu12061718", "PMC7352781", "32521760"]}, {"Citation": "Mak J.W.Y., Chan F.K.L., Ng S.C. Probiotics and COVID-19: One size does not fit all. Lancet Gastroenterol. Hepatol. 2020;5:644\u2013645. doi: 10.1016/S2468-1253(20)30122-9.", "ArticleIdList": ["10.1016/S2468-1253(20)30122-9", "PMC7182525", "32339473"]}, {"Citation": "Di Renzo L., Merra G., Esposito E., De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Eur. Rev. Med. Pharmacol. Sci. 2020;24:4062\u20134063.", "ArticleIdList": ["32374010"]}, {"Citation": "Bauer S.R., Kapoor A., Rath M., Thomas S.A. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? Clevel. Clin. J. Med. 2020 doi: 10.3949/ccjm.87a.ccc046. online ahead of print.", "ArticleIdList": ["10.3949/ccjm.87a.ccc046", "32513807"]}, {"Citation": "Rogero M.M., Le\u00e3o M.C., Santana T.M., Pimentel M.V.M.B., Carlini G.C.G., da Silveira T.F.F., Gon\u00e7alves R.C., Castro I.A. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. Free Radic. Biol. Med. 2020;156:190\u2013199. doi: 10.1016/j.freeradbiomed.2020.07.005.", "ArticleIdList": ["10.1016/j.freeradbiomed.2020.07.005", "PMC7350587", "32653511"]}, {"Citation": "Messina G., Polito R., Monda V., Cipolloni L., Di Nunno N., Di Mizio G., Murabito P., Carotenuto M., Messina A., Pisanelli D., et al. Functional Role of Dietary Intervention to Improve the Outcome of COVID-19: A Hypothesis of Work. Int. J. Mol. Sci. 2020;21:3104. doi: 10.3390/ijms21093104.", "ArticleIdList": ["10.3390/ijms21093104", "PMC7247152", "32354030"]}, {"Citation": "Boukhatem M.N., Setzer W.N. Aromatic Herbs, Medicinal Plant-Derived Essential Oils, and Phytochemical Extracts as Potential Therapies for Coronaviruses: Future Perspectives. Plants. 2020;9:800. doi: 10.3390/plants9060800.", "ArticleIdList": ["10.3390/plants9060800", "PMC7356962", "32604842"]}, {"Citation": "Santini A., Cammarata S.M., Capone G., Ianaro A., Tenore G.C., Pani L., Novellino E. Nutraceuticals: Opening the debate for a regulatory framework. Br. J. Clin. Pharmacol. 2018;84:659\u2013672. doi: 10.1111/bcp.13496.", "ArticleIdList": ["10.1111/bcp.13496", "PMC5867125", "29433155"]}, {"Citation": "Xiong X., Wang P., Su K., Cho W.C., Xing Y. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis. Pharmacol. Res. 2020;160:105056. doi: 10.1016/j.phrs.2020.105056.", "ArticleIdList": ["10.1016/j.phrs.2020.105056", "PMC7331568", "32622723"]}, {"Citation": "Ang L., Song E., Lee H.W., Lee M.S. Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J. Clin. Med. 2020;9:1583. doi: 10.3390/jcm9051583.", "ArticleIdList": ["10.3390/jcm9051583", "PMC7290825", "32456123"]}, {"Citation": "Wyganowska-Swiatkowska M., Nohawica M., Grocholewicz K., Nowak G. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review. Int. J. Mol. Sci. 2020;21:4639. doi: 10.3390/ijms21134639.", "ArticleIdList": ["10.3390/ijms21134639", "PMC7370028", "32629817"]}, {"Citation": "Yang Y. Use of herbal drugs to treat COVID-19 should be with caution. Lancet. 2020;395:1689\u20131690. doi: 10.1016/S0140-6736(20)31143-0.", "ArticleIdList": ["10.1016/S0140-6736(20)31143-0", "PMC7228688", "32422123"]}, {"Citation": "Kumar A., Kubota Y., Chernov M., Kasuya H. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Med. Hypotheses. 2020;144:109848. doi: 10.1016/j.mehy.2020.109848.", "ArticleIdList": ["10.1016/j.mehy.2020.109848", "PMC7247509", "32512490"]}, {"Citation": "D\u2019Cruze H., Arroll B., Kenealy T. Is intranasal zinc effective and safe for the common cold? A systematic review and meta-analysis. J. Prim. Health Care. 2009;1:134\u2013139. doi: 10.1071/HC09134.", "ArticleIdList": ["10.1071/HC09134", "20690364"]}, {"Citation": "Turner R.B. Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds. Clin. Infect. Dis. 2001;33:1865\u20131870. doi: 10.1086/324347.", "ArticleIdList": ["10.1086/324347", "11692298"]}, {"Citation": "Alexander T.H., Davidson T.M. Intranasal zinc and anosmia: The zinc-induced anosmia syndrome. Laryngoscope. 2006;116:217\u2013220. doi: 10.1097/01.mlg.0000191549.17796.13.", "ArticleIdList": ["10.1097/01.mlg.0000191549.17796.13", "16467707"]}, {"Citation": "Asif M., Saleem M., Saadullah M., Yaseen H.S., Al Zarzour R. COVID-19 and therapy with essential oils having antiviral, anti-inflammatory, and immunomodulatory properties. Inflammopharmacology. 2020;28:1153\u20131161. doi: 10.1007/s10787-020-00744-0.", "ArticleIdList": ["10.1007/s10787-020-00744-0", "PMC7427755", "32803479"]}, {"Citation": "Silva J.K.R.D., Figueiredo P.L.B., Byler K.G., Setzer W.N. Essential Oils as Antiviral Agents. Potential of Essential Oils to Treat SARS-CoV-2 Infection: An In-Silico Investigation. Int. J. Mol. Sci. 2020;21:3426. doi: 10.3390/ijms21103426.", "ArticleIdList": ["10.3390/ijms21103426", "PMC7279430", "32408699"]}, {"Citation": "Bilia A.R., Guccione C., Isacchi B., Righeschi C., Firenzuoli F., Bergonzi M.C. Essential oils loaded in nanosystems: A developing strategy for a successful therapeutic approach. Evid. Based Complement. Altern. Med. 2014;2014:651593. doi: 10.1155/2014/651593.", "ArticleIdList": ["10.1155/2014/651593", "PMC4058161", "24971152"]}, {"Citation": "Kaur M., Devi G., Nagpal M., Singh M., Dhingra G.A., Aggarwal G. Antiviral essential oils incorporated in nanocarriers: Strategy for prevention from COVID-19 and future infectious pandemics. Pharm. Nanotechnol. 2020 doi: 10.2174/2211738508666201016151850. online ahead of print.", "ArticleIdList": ["10.2174/2211738508666201016151850", "33069206"]}, {"Citation": "Severino P., Andreani T., Chaud M.V., Benites C.I., Pinho S.C., Souto E.B. Essential oils as active ingredients of lipid nanocarriers for chemotherapeutic use. Curr. Pharm. Biotechnol. 2015;16:365\u2013370. doi: 10.2174/1389201016666150206111253.", "ArticleIdList": ["10.2174/1389201016666150206111253", "25658380"]}, {"Citation": "Mart\u00ednez-S\u00e1nchez G., Schwartz A., Donna V.D. Potential Cytoprotective Activity of Ozone Therapy in SARS-CoV-2/COVID-19. Antioxidants. 2020;9:389. doi: 10.3390/antiox9050389.", "ArticleIdList": ["10.3390/antiox9050389", "PMC7278582", "32384798"]}, {"Citation": "Valdenassi L., Franzini M., Ricevuti G., Rinaldi L., Galoforo A.C., Tirelli U. Potential mechanisms by which the oxygen-ozone (O2-O3) therapy could contribute to the treatment against the coronavirus COVID-19. Eur. Rev. Med. Pharmacol. Sci. 2020;24:4059\u20134061.", "ArticleIdList": ["32374009"]}, {"Citation": "Semple J.L., Moore G.W.K. High levels of ambient ozone (O3) may impact COVID-19 in high altitude mountain environments. Respir. Physiol. Neurobiol. 2020;280:103487. doi: 10.1016/j.resp.2020.103487.", "ArticleIdList": ["10.1016/j.resp.2020.103487", "PMC7324919", "32619691"]}, {"Citation": "Istituto Superiore di Sanit\u00e0  23 Luglio 2020. Rapporto ISS COVID-19 \u2022 n. 56/2020. Focus on: Utilizzo Professionale Dell\u2019ozono Anche in Riferimento a COVID-19.  [(accessed on 4 December 2020)]; Available online:  https://www.iss.it/rapporti-covid-19/-/asset_publisher/btw1J82wtYzH/content/rapporti-iss-covid-19-n.-56-2020-focus-on-utilizzo-professionale-dell-ozono-anche-in-riferimento-al-covid-19.-versione-del-23-luglio-2020.-gruppo-di-lavoro-iss-inail."}, {"Citation": "Zheng Z., Dong M., Hu K. A preliminary evaluation on the efficacy of ozone therapy in the treatment of COVID-19. J. Med. Virol. 2020 doi: 10.1002/jmv.26040. online ahead of print.", "ArticleIdList": ["10.1002/jmv.26040", "PMC7280732", "32437014"]}, {"Citation": "ISCO3  Uso Potenziale di Ozono Nella SARS-CoV-2/COVID-19. Madrid, 2020. Comitato Scientifico Internazionale di Ozonoterapia.  [(accessed on 4 December 2020)]; Available online:  www.isco3.org."}, {"Citation": "Zafar S., Arshad M.S., Fatima S., Ali A., Zaman A., Sayed E., Chang M.W., Ahmad Z. COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. Pharmaceutics. 2020;12:945. doi: 10.3390/pharmaceutics12100945.", "ArticleIdList": ["10.3390/pharmaceutics12100945", "PMC7601382", "33023033"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "1", "Day": "20"}, {"Year": "2021", "Month": "2", "Day": "18"}, {"Year": "2021", "Month": "2", "Day": "21"}, {"Year": "2021", "Month": "3", "Day": "6", "Hour": "1", "Minute": "3"}, {"Year": "2021", "Month": "3", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "3", "Day": "7", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "2", "Day": "25"}], "PublicationStatus": "epublish", "ArticleIdList": ["33668969", "PMC7996547", "10.3390/pharmaceutics13030302", "pharmaceutics13030302"]}}], "PubmedBookArticle": []}